Safety and efficacy of camrelizumab and apatinib in combination with IMRT in unresectable hepatocellular carcinoma: A non-randomised phase 2 study.

被引：0
|
作者：
Wang, Wei-Hu
Xing, Baocai
Wang, Hongzhi
Zhu, Xianggao
Wang, Kun
Zheng, Xuan
Dong, Dezuo
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Radiat Oncol, Beijing, Peoples R China
[2] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Hepatopancreatobiliary Surg Unit 1, Minist Educ Beijing, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16157
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell lung cancer: A phase II study.
    Ni, Jun
    Zhang, Xiaotong
    Pan, Ruili
    Wang, Hanping
    Si, Xiaoyan
    Cui, Xiaoxia
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Efficacy and safety of vitamin K with sorafenib combination treatment against hepatocellular carcinoma: Open-label, randomized phase II study.
    Haruna, Yoshimichi
    Inoue, Atsuo
    Kawamoto, Seiichi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
    Tang, Lin-Quan
    Jia, Guo-Dong
    Lv, Xiao-Fei
    Xie, Siyi
    Chen, Yu
    Li, Ji-Bin
    Li, Xiao Yun
    Zhu, Manyi
    Liu, Sai Lan
    Liu, LiTing
    Sun, Xue-Song
    Guo, Shanshan
    Luo, Dong-Hua
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
    Yu, Jiahui
    Yan, Duan
    Wei, Song
    Yang, Linfeng
    Yi, Pengsheng
    ONCOLOGY LETTERS, 2024, 28 (02)
  • [45] Preliminary data of a phase Ib/II trial evaluating the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular carcinoma
    Long, Yin
    Yang, Qiong
    Huang, Ziqi
    He, Xiaodong
    Huang, Jue
    Liao, Jianguo
    Chen, Yajin
    Hu, Hai
    Zhang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
    Huang, Jian
    Wang, Zhen-Guang
    Tao, Qi-Fei
    Yang, Yun
    Yuan, Sheng-Xian
    Gu, Fang-Ming
    Liu, Hui
    Pan, Ze-Ya
    Jiang, Bei-Ge
    Lau, Wan Yee
    Zhou, Wei-Ping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [47] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
    Cao, Yajuan
    Zhang, Xuebin
    Yue, Yang
    Peng, Jin
    Li, Binghua
    Shi, Jiong
    Tang, Min
    Chen, Chaobo
    Su, Ke
    Zhang, Laizhu
    Cheng, Chunxiao
    Yu, Decai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [48] Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
    Thomas, Melanie B.
    Chadha, Romil
    Glover, Katrina
    Wang, Xuemei
    Morris, Jeffrey
    Brown, Thomas
    Rashid, Asif
    Dancey, Janet
    Abbruzzese, James L.
    CANCER, 2007, 110 (05) : 1059 - 1067
  • [49] Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety
    Liu, Song
    Zhao, Guangsheng
    Yu, Guangji
    Guo, Nannan
    Zhang, Yuewei
    Li, Qiang
    Wang, Zhe
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1165 - 1170
  • [50] Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).
    Zhang, Yun
    Xu, Jianming
    Shen, Jie
    Gu, Shanzhi
    Wu, Lihua
    Wu, Jian
    Shao, Guoliang
    Zhang, Yanqiao
    Xu, Li
    Yin, Tao
    Liu, Jingfeng
    Ren, Zhenggang
    Xiong, Jianping
    Mao, Xianhai
    Zhang, Ling
    Yang, Jiayin
    Li, Lequn
    Chen, Xiaoming
    Wang, Zhiming
    Wang, Quanren
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345